Kyowa Kirin Co Ltd
TSE:4151

Watchlist Manager
Kyowa Kirin Co Ltd Logo
Kyowa Kirin Co Ltd
TSE:4151
Watchlist
Price: 2 379.5 JPY -0.27%
Market Cap: 1.3T JPY
Have any thoughts about
Kyowa Kirin Co Ltd?
Write Note

Kyowa Kirin Co Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Kyowa Kirin Co Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Kyowa Kirin Co Ltd
TSE:4151
Net Income (Common)
ÂĄ83.5B
CAGR 3-Years
25%
CAGR 5-Years
6%
CAGR 10-Years
16%
Takeda Pharmaceutical Co Ltd
TSE:4502
Net Income (Common)
ÂĄ290B
CAGR 3-Years
-15%
CAGR 5-Years
28%
CAGR 10-Years
12%
Daiichi Sankyo Co Ltd
TSE:4568
Net Income (Common)
ÂĄ250.4B
CAGR 3-Years
42%
CAGR 5-Years
17%
CAGR 10-Years
12%
Otsuka Holdings Co Ltd
TSE:4578
Net Income (Common)
ÂĄ151.6B
CAGR 3-Years
1%
CAGR 5-Years
6%
CAGR 10-Years
-1%
Chugai Pharmaceutical Co Ltd
TSE:4519
Net Income (Common)
ÂĄ387B
CAGR 3-Years
15%
CAGR 5-Years
23%
CAGR 10-Years
22%
Astellas Pharma Inc
TSE:4503
Net Income (Common)
ÂĄ54.7B
CAGR 3-Years
-23%
CAGR 5-Years
-26%
CAGR 10-Years
-7%
No Stocks Found

Kyowa Kirin Co Ltd
Glance View

Market Cap
1.2T JPY
Industry
Pharmaceuticals

Kyowa Kirin Co., Ltd. stands as a notable presence in the global pharmaceutical landscape, having evolved from its roots in Japan into a significant force in medical innovation. This company, originally established from the merger of Kyowa Hakko Kogyo and Kirin Pharma, focuses on the development and commercialization of biopharmaceuticals that tackle complex medical conditions, primarily within the fields of oncology, nephrology, immunology, and neurology. With a strategy deeply rooted in research and development, Kyowa Kirin harnesses its proprietary antibody technologies and innovative approaches to deliver therapeutic solutions, fostering partnerships that expand its impact and reach. Their commitment to scientific progress is supplemented by a robust pipeline of investigational drugs, demonstrating their dedication to addressing unmet medical needs. Kyowa Kirin operates primarily on a business model that derives revenues from the successful commercialization of its pharmaceutical products. The company navigates the delicate balance between high-stakes investment in R&D and the potential high rewards that come from developing effective new treatments. By consistently bringing innovative therapies to market, they generate revenue through direct sales, collaborations, and licensing agreements within both domestic and international spheres. Additionally, their strategic alliances with biotech firms and research institutions globally enable them to enhance their R&D capabilities, ensuring a steady flow of new drugs that sustain their growth and solidify their competitive edge in the highly regulated and competitive pharmaceutical sector.

Intrinsic Value
3 567.82 JPY
Undervaluation 33%
Intrinsic Value
Price

See Also

What is Kyowa Kirin Co Ltd's Net Income (Common)?
Net Income (Common)
83.5B JPY

Based on the financial report for Sep 30, 2024, Kyowa Kirin Co Ltd's Net Income (Common) amounts to 83.5B JPY.

What is Kyowa Kirin Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
16%

Over the last year, the Net Income (Common) growth was 44%. The average annual Net Income (Common) growth rates for Kyowa Kirin Co Ltd have been 25% over the past three years , 6% over the past five years , and 16% over the past ten years .

Back to Top